Cover Image
市場調查報告書

胰島素抗性:開發平台分析

Insulin Resistance - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245980
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
胰島素抗性:開發平台分析 Insulin Resistance - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 49 Pages
簡介

胰島素抗性(IR),是身體的細胞對胰島素的效果表示抗性的狀態。可觀察到倦怠感、空腹、集中力的缺乏、高血壓等症狀。原因為肥胖和高血壓。

本報告提供胰島素抗性的治療藥的開發情形調查分析、開發中產品的概要、臨床實驗的各階段的產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

胰島素抗性概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • AUS Bio Limited
  • Genfit SA
  • GlaxoSmithKline Plc
  • Hadasit Medical Research Services & Development Ltd
  • Mertiva AB
  • Mochida Pharmaceutical Co., Ltd.
  • Novartis AG
  • Prometheon Pharma, LLC
  • Sanofi

治療藥的評估

  • 單獨療法的情況
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 6860766
  • BVS-857
  • Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis
  • Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders
  • elafibranor
  • englerin A
  • MD-960
  • Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders
  • PEG-Catalase
  • Peptide for Obesity and Insulin Resistance
  • SAR-088
  • SERX-1
  • Small Molecule for Hypertension and Insulin Resistance
  • Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation
  • Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders
  • Small Molecule to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular
  • Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders
  • Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders
  • Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8267IDB

Summary

Global Markets Direct's, 'Insulin Resistance - Pipeline Review, H2 2016', provides an overview of the Insulin Resistance pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Insulin Resistance, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Insulin Resistance
  • The report reviews pipeline therapeutics for Insulin Resistance by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Insulin Resistance therapeutics and enlists all their major and minor projects
  • The report assesses Insulin Resistance therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Insulin Resistance

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Insulin Resistance
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Insulin Resistance Overview
  • Therapeutics Development
    • Pipeline Products for Insulin Resistance - Overview
    • Pipeline Products for Insulin Resistance - Comparative Analysis
  • Insulin Resistance - Therapeutics under Development by Companies
  • Insulin Resistance - Therapeutics under Investigation by Universities/Institutes
  • Insulin Resistance - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Insulin Resistance - Products under Development by Companies
  • Insulin Resistance - Products under Investigation by Universities/Institutes
  • Insulin Resistance - Companies Involved in Therapeutics Development
    • Atara Biotherapeutics, Inc.
    • AUS Bio Limited
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • Hadasit Medical Research Services & Development Ltd
    • Sanofi
  • Insulin Resistance - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ATA-842 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • englerin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FC-98 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-444217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-2286 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MD-960 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MD-961 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide for Obesity and Insulin Resistance - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7992 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Hypertension and Insulin Resistance - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYM-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Insulin Resistance - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Insulin Resistance, H2 2016
  • Number of Products under Development for Insulin Resistance - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Insulin Resistance - Pipeline by Atara Biotherapeutics, Inc., H2 2016
  • Insulin Resistance - Pipeline by AUS Bio Limited, H2 2016
  • Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Insulin Resistance - Pipeline by Gilead Sciences, Inc., H2 2016
  • Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016
  • Insulin Resistance - Pipeline by Sanofi, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Insulin Resistance - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Insulin Resistance, H2 2016
  • Number of Products under Development for Insulin Resistance - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top